Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Stealth BioTherapeutics Inc. is currently managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This structure indicates that each pending matter is being evaluated independently by different personnel in separate technical divisions, rather than being clustered under a single examiner or art unit. This distribution suggests that the company's current pharmaceutical-related filings are technically diverse.
The busiest examiner for this portfolio is REYNOLDS, FRED H, who is responsible for 1 pending office action. Because there are 2 pending office actions and 2 distinct examiners, the workload is evenly split between the involved officials. The presence of 2 distinct art units for 2 actions confirms that the company's current prosecution activity is spread across different specialized departments. This level of distribution requires the company to navigate different examiner styles and art unit practices for its pending matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REYNOLDS, FRED H | 1 | 32.9% | +39.3% |
| LEE, WILLIAM Y | 1 | 48.0% | +34.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18568502 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF VARIOUS MITOCHONDRIAL DISEASES OR DISORDERS, INCLUDING FRIEDREICH'S ATAXIA | LEE, WILLIAM Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18891617 | CRYSTALLINE SALT FORMS OF BOC-D-ARG-DMT-LYS-(BOC)-PHE-NH2 | REYNOLDS, FRED H | — |
| 18568502 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF VARIOUS MITOCHONDRIAL DISEASES OR DISORDERS, INCLUDING FRIEDREICH'S ATAXIA | LEE, WILLIAM Y | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18891617 | CRYSTALLINE SALT FORMS OF BOC-D-ARG-DMT-LYS-(BOC)-PHE-NH2 | REYNOLDS, FRED H | 1658 | §112DP | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18568502 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF VARIOUS MITOCHONDRIAL DISEASES OR DISORDERS, INCLUDING FRIEDREICH'S ATAXIA | LEE, WILLIAM Y | 1623 | §102§103§112 | Non-Final OA | — | Pending | Dec 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialStealth BioTherapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Fred H Reynolds has the most, with 1 of Stealth BioTherapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
